Empath Ventures
Empath Ventures (operating as XEIA Venture Partners) is a US venture capital firm founded in 2021 that invests in life sciences, AI, and health tech startups advancing its 'Human 3' thesis in neurobiology, brain-computer interfaces, psychedelic therapies, and concierge medicine, serving early-stage founders and undisclosed limited partners.
- Company typePrivate
- Founded2021
- HeadquartersLos Angeles, United States
- Headcount—
- GTM typeB2B
- OfferingServices
What Empath Ventures does
Empath Ventures, operating as XEIA Venture Partners (XEIA Venture Partners, LLC), is a privately held US venture capital firm founded in 2021 and headquartered in Los Angeles. The firm invests across life sciences, AI, hardware, software, deep tech, and health tech, organized around a proprietary thematic thesis the firm calls 'Human 3' — framed as a new epoch of health, wellbeing, and performance advanced through neurobiology, brain-computer interfaces, psychedelic therapies, and concierge medicine technologies. The firm serves early-stage founders building companies in these sectors and, on the LP side, attracts capital from limited partners (LPs) whose identity is not publicly disclosed.
The firm's product is its portfolio and the strategic guidance it provides to portfolio companies. The disclosed portfolio comprises four companies: NeuroBionics (minimally invasive brain-computer interfaces), Superpower (concierge medicine), Motif (neurotechnology targeting depression), and Mindstate Design Labs (precision psychedelic therapies). The firm itself does not sell a software or services product; it is an investment manager. Its business model follows standard venture capital economics — generating revenue through management fees on committed capital and carried interest on investment returns — rather than through product pricing.
The firm is founder-led and lean. The team comprises Brom Rector, CFA (Founding Partner, positioned as the firm's AI/ML expert), Sam Rector (Partner, a medicinal chemist and psychoactive pharmacologist), and Li-Huei Tsai, PhD (Scientific Advisor, Director of MIT's Aging Brain Initiative), giving the firm a distinctive combination of AI/ML and neuroscience/pharmacology expertise for a small niche manager. Distribution is driven by content marketing — a website (xeiavp.com), blog, the Focal Points Podcast, YouTube channel, and email newsletter — used to broadcast the Human 3 thesis and attract both founders and LPs. There is no disclosed fund size, AUM, headcount beyond the named team, fund vintage cadence, or financial performance, so the firm's scale and institutional maturity are not publicly verifiable from the available data.
Empath Ventures firmographics
Firmographics- Name
- Empath Ventures
- Legal name
- XEIA Venture Partners, LLC
- Website
- https://empath.vc
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Short description
- Empath Ventures (operating as XEIA Venture Partners) is a US venture capital firm founded in 2021 that invests in life sciences, AI, and health tech startups advancing its 'Human 3' thesis in neurobiology, brain-computer interfaces, psychedelic therapies, and concierge medicine, serving early-stage founders and undisclosed limited partners.
- Ownership category
- akta.pro rank
Empath Ventures industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Empath Ventures is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Markets served
Empath Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
Marketing channels3 records
Empath Ventures product offering
Product offeringCore offering
Empath Ventures (operating as XEIA Venture Partners) is a venture capital firm that invests in early-stage companies across life sciences, AI, hardware, software, deep tech, and health tech. The firm pursues a thematic investment thesis called 'Human 3', focusing on neurobiology, brain-computer interfaces, psychedelic therapies, and concierge medicine to advance the next epoch of health, wellbeing, and performance.
Product overview
Empath Ventures (operating as XEIA Venture Partners) is a venture capital firm that invests in life sciences, AI, hardware, software, deep tech, and health tech to advance 'Human 3' - described as the new epoch of health, wellbeing and performance. The firm manages a portfolio of four portfolio companies: NeuroBionics (brain-computer interfaces), Superpower (concierge medicine), Motif (neurotech for depression), and Mindstate Design Labs (precision psychedelic therapies). Rather than operating a unified platform, the company functions as a venture investment firm with a thematic focus, supporting these portfolio companies through capital and strategic guidance.
Differentiator
Problem solved
Functional benefit
Products and services
- NeuroBionics
- Superpower
- Motif
- Mindstate Design Labs
Companies that use Empath Ventures
Customer profileSegments1 record
Ideal customer profiles2 records
Empath Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Empath Ventures partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Empath Ventures competitors and assessment
Company assessmentDirect peers
- Ambria Capital: Venture firm investing in psychedelic science, mental health, and wellness. Overlaps with XEIA on psychedelic therapy and concierge medicine exposure within the Human 3 thesis.
- Negev Capital: A venture capital fund dedicated to psychedelic medicine and mental health therapies. Closely comparable to XEIA's psychedelic-medicine bet via Mindstate Design Labs and Sam Rector's pharmacology expertise.
- PsyMed Ventures: Early-stage VC focused on psychedelic medicine and mental health startups. A direct competitor in the same niche, targeting founders and LPs with overlapping mandates to XEIA.
- JLS Fund: Psychedelic-medicine-focused venture fund backing startups developing psilocybin, MDMA, and related therapies. Direct competitor for psychedelic therapy deal flow relevant to XEIA's portfolio.
- Vine Ventures: Thesis-driven, small venture fund focused on psychedelic and mental-health innovation. Closely comparable to XEIA in fund size, thematic clarity, and psychedelic-medicine deal focus.
- Iter Investments: Psychedelic and plant-medicine focused venture fund. Competes directly for psychedelic therapy deals and LP mindshare aligned with XEIA's psychedelic medicine thesis.
Broad incumbents
- Founders Fund: Thematic deep tech and frontier-technology venture firm. Comparable to XEIA's interest in brain-computer interfaces and longevity, but operating as a generalist across multiple frontier categories.
- Lux Capital: Sector-focused VC investing in deep tech, health, and neurotechnology. Comparable to XEIA on the brain-computer interface / neurotech side of the Human 3 thesis, though at materially larger fund scale.
- Andreessen Horowitz Bio + Health Fund: Large, established venture firm with a dedicated bio and health fund investing broadly across life sciences, digital health, and biotech. Overlaps with XEIA on neurobiology and health tech, but at much greater scale.
- Khosla Ventures: Sector-agnostic, science-driven VC with significant health, biotech, and longevity exposure. Competes with XEIA for high-science health tech founders while operating with much larger funds and broader mandates.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Empath Ventures social profiles
Digital presenceEmpath Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Empath Ventures leadership team
Management profileNumber of profiles
Profiles3 records
Empath Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Empath Ventures M&A and investment
M&A and investmentM&A
Investments18 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Empath Ventures
What does Empath Ventures do?
Empath Ventures (operating as XEIA Venture Partners) is a venture capital firm that invests in early-stage companies across life sciences, AI, hardware, software, deep tech, and health tech. The firm pursues a thematic investment thesis called 'Human 3', focusing on neurobiology, brain-computer interfaces, psychedelic therapies, and concierge medicine to advance the next epoch of health, wellbeing, and performance.
Is Empath Ventures a public or private company?
Empath Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Empath Ventures founded?
Empath Ventures was founded in 2021.
Where is Empath Ventures based?
Empath Ventures is headquartered in Los Angeles, United States, in the North America region.
Who are Empath Ventures's main competitors?
Direct peers on record are Ambria Capital, Negev Capital, PsyMed Ventures, JLS Fund, Vine Ventures and Iter Investments. Broad incumbents are Founders Fund, Lux Capital, Andreessen Horowitz Bio + Health Fund and Khosla Ventures.
Does Empath Ventures have an API?
No public API is recorded for Empath Ventures.
What industry is Empath Ventures in?
Empath Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.